Griesinger F, Eberhardt W, Nusch A, et al. - In non-small cell lung cancer (NSCLC), there has been an increasing number of treatment-determining biomarkers found and molecular testing should be done to allow optimal individualized treatment, so researchers sought to provide comprehensive details on the frequency, methodology and results of biomarker testing of advanced NSCLC in Germany. In this analysis, 3,717 patients with advanced NSCLC (2,921 non-squamous; 796 squamous) were included who were recruited into the CRISP registry at initiation of systemic therapy by 150 German sites between December 2015 and June 2019. Testing for biomarkers was done in 90.5% of the patients, with testing rates of 92.2% (non-squamous), 70.7% (squamous) observed, and the rates went from 83.2% in 2015-2016 to 94.2% in 2019. For EGFR, ALK, ROS1, and BRAF, overall testing rates of 72.5%, 74.5%, 66.1%, and 53.0%, respectively (non-squamous), were observed. For PD-L1 expression, they noted testing rates of 64.5% (non-squamous), and 58.5% (squamous). Immunohistochemistry (68.5% non-squamous, 58.3% squamous), and next-generation sequencing (38.7% non-squamous, 14.4% squamous) were the most common testing methods. There were 17.7% of patients who presented with a druggable alteration. Longer median PFS was observed for patients with a druggable EGFR or ALK alteration. Overall, observations suggest testing rates in Germany, which are acceptable when compared internationally, are high nationwide. However, a significant portion of patients who could potentially benefit are still left out; specific measures to enhance implementation are needed.